

## IN THE CLAIM

1. (currently amended): A solid pharmaceutical dosage form which comprises an opiate, an opiate antagonist and an amount of [[a]] hydrocolloids ~~containing~~ and other excipients comprising starch, lactose, xanthan gum, locust bean gum, monobasic calcium phosphate, dibasic calcium phosphate, microcrystalline cellulose, propylene glycol alginate, zein and magnesium stearate which ~~is~~ are effective to form a viscous, non-injectable matrix when said dosage form is contacted with water.
2. (original): A solid pharmaceutical dosage form as defined in claim 1 wherein the opiate is elected from the group consisting of morphine, codeine, dilaudid, pantopon, methadone, paregoric, pentazocine, buprenorphine, fentanyl, oxycodone, oxymorphone, hydromorphone, hydrocodone, propoxyphene, nalbuphine and meperidine.
3. (original): A solid pharmaceutical dosage form as defined in claim 2 wherein the opiate is oxycodone.
4. (currently amended): A solid pharmaceutical dosage form as defined in claim 1 wherein the opiate antagonist ~~is selected from the group consisting of naloxone, naltrexone, methylnaltrexone and nalexonazine~~ oxycodone.
5. (original): A solid pharmaceutical dosage form as defined in claim 4 wherein the opiate antagonist is naloxone.

6. (currently amended): A solid pharmaceutical dosage form as defined in claim 1 which includes an amount of enteric coated opiate antagonist pellets which is effective to ~~prevent~~ reduce or eliminate opiate induced constipation the constipating effects of oycodone, methadone, morphine, codeine, dilaudid, pantopon, paregoric, pentazocine, buprenorphine, fentanyl, oxymorphone, hydromorphone, hydrocodone, propoxyphene, nalbuphine and meperidine.

7-15 (canceled)

16. (currently amended): A solid pharmaceutical dosage form which comprises a controlled release dosage form of an opiate, an opiate antagonist and a hydrocolloid and excipients as defined in claim 1, wherein said opiate, an opiate antagonist, and hydrocolloid and excipients are formulated into pellets (a); pellets (b) and pellets (c);

pellets (a) comprise about one-third of said opiate, opiate antagonist and hydrocolloid in an immediate release form;

pellets (b) comprise about one-third of said opiate, opiate antagonist, and hydrocolloid and excipients in an a delayed release form which releases substantially all contents of the pellets in the jejunum; and

pellets (c) comprise about one-third of said opiate, opiate antagonist, and hydrocolloid and excipients in a delayed release form which substantially all of the contents of the pellets in the ileum.

17. (original): A solid dosage form as defined in claim 16 wherein the opiate is oxycodone and the opiate antagonist is naloxone.

18. (currently amended): A method of preventing the formulation of an parenteral formulation of a solid oral dosage form of an opiate, said method comprising adding a hydrocolloid-excipient combination to a solid oral dosage formulation of an opiate so that when said solid oral dosage form contacts water, a matrix is formed which is too viscous to be injected via a hypodermic needle.

19-20 (canceled)

21. (new): A solid pharmaceutical dosage form as defined in claim 1 wherein the opiate antagonist is selected from the group consisting of naloxone, naltrexone, methylnaltrexone and naloxonazine.

22. (new): A method of reducing or eliminating constipation caused by opiates which comprises administering a solid pharmaceutical dosage form as defined in claim 1 which includes an amount of enteric coated opiate antagonist pellets which is effective to reduce or eliminate the constipating effects of oycodone, methadone, morphine, codeine, dilaudid, pantopon, paregoric, pentazocine, buprenorphine, fentanyl, oxymorphone, hydromorphone, hydrocodone, propoxyphene , nalbuphine and meperidine.